Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

MLA

Olszewski, Adam J., et al. “Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.” Blood, vol. 136, no. Supplement 1, Nov. 2020, pp. 43–45. EBSCOhost, https://doi.org/10.1182/blood-2020-136255.

APA

Olszewski, A. J., Avigdor, A., Babu, S., Levi, I., Abadi, U., Holmes, H., McKinney, M., McCord, R., Xie, Y., Chen, C., Sarouei, K., Qayum, N., O’Hear, C., Sellam, G., & Eradat, H. (2020). Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. Blood, 136(Supplement 1), 43–45. https://doi.org/10.1182/blood-2020-136255

Chicago

Olszewski, Adam J, Abraham Avigdor, Sunil Babu, Itai Levi, Uri Abadi, Houston Holmes, Matthew McKinney, et al. 2020. “Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.” Blood 136 (Supplement 1): 43–45. doi:10.1182/blood-2020-136255.